RNA therapeutics – The potential treatment for myocardial infarction
Name
1-s2.0-S2352320416000250-main.pdf
Description
Published version
Size
905.2 KB
Format
Adobe PDF
Checksum (MD5)
6192c429b9b1b4f4c7ebb722e4df74cf
Author(s)
Chu, Hunghao
Kohane, Daniel S
Langer, Robert
Date Issued
2016
Journal
Regenerative Therapy
Publisher
Elsevier BV
Version
Final published version
Abstract
© 2016 The Japanese Society for Regenerative Medicine. RNA therapeutics mainly control gene expression at the transcript level. In contrast to conventional gene therapy which solely increases production of a protein, delivered RNAs can enhance, reduce or abolish synthesis of a particular protein, which control its relevant activities in a more diverse fashion. Thus, they hold promise to treat many human diseases including myocardial infarction (MI). MI is a serious health burden that causes substantial morbidity and mortality. An unmet clinical need for treating MI is the recovery of cardiac function, which requires regeneration of the functional tissues including the vasculature, nerves, and myocardium. Several classes of RNA therapeutics have been investigated in preclinical MI models, and the results have demonstrated their benefits and encourage their future development. In this review, we summarize the common RNA therapeutic approaches and highlight their application in MI therapy.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.RETH.2016.03.002
